Posted by Michael Wonder on 26 Jun 2023
Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over
26 June 2023 - Shingrix (recombinant zoster vaccine) is already approved in Japan for adults aged 50 and over.
GSK today announced that the Japanese MHLW has approved an updated indication for Shingrix (recombinant zoster vaccine, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and over who are at increased risk of the condition.
